Samsung Biologics

Articles

Explore how Samsung Biologics’ DEVELOPICK™ can help mitigate development risk and identify candidates with the best potential for advancement to IND and beyond

DEVELOPICK™: High-throughput developability assessment to enable efficient formulation development

In this webinar, we will discuss the known sources of β-glucan and highlight downstream processes that can reduce β-glucan. We will also address how to reduce false-positive results.

https://www.pharmtech.com/pt_w/recognizing

β-glucan process-related impurities introduced into pharmaceutical products during manufacturing can cause false-positive results on endotoxin tests. In this webinar, we will discuss the known sources of β-glucan and which downstream processes can reduce β-glucan. We will also address how to reduce false-positive results.


Senior scientist (MSAT DSP)
Samsung Biologics


 is a senior scientist in MSAT DSP at Samsung Biologics since 2019. He obtained his Ph.D. in Biotechnology from Yonsei University in Korea. He has extensive experience in downstream process tech transform from 10L lab scale to 15,000L GMP scale.

Webcasts

Webinar Date/Time: Wednesday May 31, 2023 at 11am EDT | 10am CDT | 8am PDT

Recognizing β-glucan Impurities in Biopharmaceuticals

This webinar will highlight the challenges in in the field of mRNA-based therapeutics, a strategy to design mRNA-LNP process for at-scale manufacturing, and the importance of end-to-end service.

https://globalmeet.webcasts.com/starthere.jsp?ei=1584222&tp_key=4b27ce8751

CDMO competition can be expected to intensify since mRNA manufacturing capacity and CDMOs’ capabilities both expanded significantly to meet the need associated with the pandemic. From a technical standpoint, the processes associated with mRNA manufacture generally are still new; this is pioneering work. This webinar will highlight the challenges in in the field of mRNA-based therapeutics, a strategy to design mRNA-LNP process for at-scale manufacturing, and the importance of end-to-end service. Lastly, the in-house capability of Samsung Biologics as mRNA CDMO company will be introduced.


Criteria to consider when choosing a mRNA CDMO partner

Importance of the end-to-end CDMO service

Samsung Biologics mRNA services’ Strength

Executive Vice President, Head of Manufacturing
Samsung Biologics

is the Executive Vice President and Head of Manufacturing at Samsung Biologics. He is a recognized industry expert with a demonstrated history of 26+ years in the biopharmaceutical and pharmaceutical industry. Prior to joining Samsung Biologics, Pierre held a leadership role at Lonza serving as the Head of the Portsmouth, NH (USA) and Porriño, Spain sites. He also served as Site Head at Virbac & Sanofi Pasteur, as well as Senior Vice President of Technical Operations & Supply Chain at Stallergenes Greer earlier in his career. Pierre holds a master's degree in general engineering from ECAM LaSalle.


 is the Senior Scientist of mRNA T/F at Samsung Biologics. After joining Samsung Biologics in 2021, she has led the tech transfer project in both lab- and at-scale lipid nanoparticle manufacturing process. She holds a Master/Ph.D degree in Chemical and Biological Engineering from Seoul National University, South Korea, and a bachelor’s degree in Chemical Engineering from University of Notre Dame, USA. 

Webinar Date/Time: Thursday, December 8, 2022 at 11am EST | 10am CST | 8 am PST


Key Considerations When Selecting an mRNA CDMO Partner

Advantages of outsourcing development projects to CDMOs,

Preventing challenges and starting the development process quickly, and

Choosing a CMO partner with a highly optimized cell line platform.


Podcasts

Samsung Biologics is responding to industry challenges with various development projects and services that improve overall timelines and efficiencies when manufacturing new medicines.



The Right Partner to Advance Your Molecule From Gene to Commercialization – The Right Step to Advance Your Molecule

The Right Partner to Advance Your Molecule From Gene to Commercialization- The Right Step to Advance Your Molecules

All drugs approved in the US marketplace went through an extensive, multi- million dollars, multi-year journey before being available to patients. In order to bring a new drug to the market place requires extensive resources, technical acumen, and an unbendable commitment to the goal. CDMOs are alongside pharma companies helping them navigate the process and mitigate risk. By choosing the right partnerships, you can give your drug production the competitive advantage it brings to the marketplace. Listen to Soojin Han, Director of the CLD group at Samsung Biologics, as she talks about what is the CDMO partnership and how Samsung Biologics can help many scientists for drug development to speed up the drug product to the marketplace and support many people's health life.